Stoke Therapeutics
Quarterly Financials
| Values in thousands | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 |
|---|---|---|---|---|
Revenue | $22,614 | $4,894 | $4,831 | $4,216 |
Gross Profit | 22,614 | 3,783 | 3,721 | 3,103 |
EBITDA | -13,127 | -30,003 | -28,794 | -27,809 |
EBIT | -13,653 | -30,543 | -29,904 | -28,922 |
Net Income | -10,482 | -26,430 | -25,695 | -26,374 |
Net Change In Cash | 22,614 | 4,894 | 4,831 | 4,216 |
Free Cash Flow | -23,235 | -21,718 | -17,523 | -24,578 |
Cash | 127,983 | 150,016 | 193,551 | 178,581 |
Basic Shares | 54,008 | 56,341 | 55,765 | 46,246 |
Annual Financials
| Values in thousands | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
Revenue | $36,555 | $8,780 | $12,405 | $3,000 |
Gross Profit | 36,555 | 8,780 | 12,405 | -2,230 |
EBITDA | -101,372 | -112,304 | -102,810 | -85,091 |
EBIT | -114,773 | -104,356 | -86,065 | |
Net Income | -88,981 | -104,699 | -93,110 | -84,711 |
Net Change In Cash | 36,555 | 8,780 | 12,405 | 3,000 |
Cost of Revenue | -31,339 | -142,049 | ||
Free Cash Flow | -87,054 | -82,683 | -35,828 | -68,107 |
Cash | 127,983 | 191,442 | 113,556 | 144,895 |
Basic Shares | 54,008 | 43,994 | 38,897 | 36,739 |
Earnings Calls
| Quarter | EPS |
|---|---|
2024-12-31 | -$0.18 |
2024-09-30 | -$0.46 |
2024-06-30 | -$0.46 |
2024-03-31 | -$0.57 |
